Suppr超能文献

对中央药品标准控制组织(CDSCO)清单中批准的固定剂量复方制剂合理性的评估。

Assessment of Rationality of Fixed Dose Combinations Approved in CDSCO List.

作者信息

Dalal Krunal, Ganguly Barna, Gor Alpa

机构信息

Resident, Department of Pharmacology, Pramukh Swami Medical College , Karamsad, Gujarat, India .

Professor and Head, Department of Pharmacology, Pramukh Swami Medical College , Karamsad, Gujarat, India .

出版信息

J Clin Diagn Res. 2016 Apr;10(4):FC05-8. doi: 10.7860/JCDR/2016/17856.7691. Epub 2016 Apr 1.

Abstract

INTRODUCTION

Fixed Dose Combination (FDC) is highly popular in the Indian pharmaceutical market and has been particularly flourishing in the last few years. Though rationality status is not clear, the pharmaceutical industry has been manufacturing and marketing FDCs.

AIM

To assess rationality of FDCs enlisted in CDSCO list and marketing in India according to pharmacokinetic (FD) and pharmacodynamic (FD) reasoning and WHO rationality criteria.

MATERIALS AND METHODS

In this study, 264 FDCs marketed in India from 2009 to 2014 from CDSCO list 2014 were included. Assessment was done on the basis of following parameters: 1) Year and system of FDC; 2) Dosage form; 3) Number of Active Pharmacological Ingredient (API); 4) Schedule of FDC; 5) The presence of the FDC and its ingredients in the WHO Essential Medicine List 2013 and National Essential Medicine List, India 2011; 6) FD and PK parameters of APIs of combination; 7) PK and PD interaction; 8) Safety parameters of ingredients in combination. Descriptive statistics in terms of frequency counts and percentages were used for variables.

RESULTS

Out of total 264 FDCs selected, maximum number of combinations (112) were approved in 2010. System wise selection showed 51 (19.31%) FDCs were from cardiovascular system followed by 46 (17.42%) from pain/musculoskeletal system. Oral dosage form was found to be maximum with 200 (75.75%) combinations. According to schedules, 154 (58.33%) combinations were categorized under schedule H. There were 210 (79.54%) FDCs that had two API which was found to be maximum, whereas, only 3 (1.13%) combinations had 5 API. We could find possible PK and PD interactions in between API of 10 (3.78%) and 73 (27.65%) combinations respectively on basis of standard textbooks and references. Similarly dose reduction in API was seen in 58 (21.96%) FDCs. There were 123 (46.59%) FDCs had chances of increased ADRs due to its API. Out of 264 combinations, 52 combinations were rational (6-9), 75 combinations were semi-rational (3-<6) and 137 combinations were found to be irrational (0<3).

CONCLUSION

We could reveal that majority of combinations approved in last six years were found to be semi-rational and irrational. It is important to carry out detailed study in this area to establish the fact and increase rationality of combinations.

摘要

引言

固定剂量复方制剂(FDC)在印度制药市场非常受欢迎,并且在过去几年中尤其繁荣。尽管其合理性状况尚不清楚,但制药行业一直在生产和销售FDC。

目的

根据药代动力学(FD)和药效学(FD)原理以及世界卫生组织的合理性标准,评估列入CDSCO清单并在印度销售的FDC的合理性。

材料与方法

本研究纳入了2014年CDSCO清单中2009年至2014年在印度销售的264种FDC。评估基于以下参数进行:1)FDC的年份和系统;2)剂型;3)活性药理成分(API)的数量;4)FDC的附表;5)FDC及其成分在《2013年世界卫生组织基本药物清单》和《2011年印度国家基本药物清单》中的情况;6)复方制剂中API的FD和PK参数;7)PK和PD相互作用;8)复方制剂中成分的安全性参数。变量采用频率计数和百分比的描述性统计方法。

结果

在总共选择的264种FDC中,2010年批准的组合数量最多(112种)。按系统分类,51种(19.31%)FDC来自心血管系统,其次是46种(17.42%)来自疼痛/肌肉骨骼系统。发现口服剂型最多,有200种(75.75%)组合。根据附表,154种(58.33%)组合被归类在H附表下。有210种(79.54%)FDC含有两种API,这是最多的,而只有3种(1.13%)组合含有5种API。根据标准教科书和参考文献,我们分别在10种(3.78%)和73种(27.65%)组合的API之间发现了可能的PK和PD相互作用。同样,在58种(21.96%)FDC中发现了API剂量减少的情况。有123种(46.59%)FDC因其API有增加不良反应的可能性。在264种组合中,52种组合是合理的(6 - 9),75种组合是半合理的(3 - <6),137种组合被发现是不合理的(0 <3)。

结论

我们可以发现,过去六年中批准的大多数组合被发现是半合理和不合理的。在这一领域进行详细研究以确定事实并提高组合的合理性很重要。

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验